Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Neurosense Therapeutics Ltd. (NRSN)
NASDAQ:NRSN
RESEARCH TOOLSreports
Neurosense Therapeutics Ltd. (NRSN) Stock Price & Analysis
65 Followers
NRSN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.40 - $2.33
Previous Close$1.7
Volume163.98K
Average Volume (3M)319.41K
Market Cap
$23.78M
Enterprise Value$19.80M
Total Cash (Recent Filing)$3.58M
Total Debt (Recent Filing)$147.00K
Price to Earnings (P/E)-1.8
Beta0.75
Next Earnings
May 29, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.92
Shares Outstanding15,379,042
10 Day Avg. Volume219,495
30 Day Avg. Volume319,411
Standard Deviation0.53
R-Squared0.03
Alpha0.08
Financial Highlights & Ratios
Price to Book (P/B)4.65
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit257.09
Enterprise Value/Ebitda-2.17
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Neurosense Therapeutics Ltd. News
PremiumCompany Announcements
NeuroSense Launches Pre-Funded Warrants Offering
PremiumCompany Announcements
NeuroSense Advances ALS Therapy with Promising Trials
PremiumCompany Announcements
NeuroSense Partners with Lonza on ALS Biomarker Research
PremiumCompany Announcements
NeuroSense’s Positive ALS Trial Results and 2023 FinancesOwnership Overview
0.00%
Insiders
0.09% Mutual Funds
0.79% Other Institutional Investors
99.13% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
NRSN FAQ
What was Neurosense Therapeutics Ltd.’s price range in the past 12 months?
Neurosense Therapeutics Ltd. lowest stock price was $0.40 and its highest was $2.33 in the past 12 months.
What is Neurosense Therapeutics Ltd.’s market cap?
Currently, no data Available
When is Neurosense Therapeutics Ltd.’s upcoming earnings report date?
Neurosense Therapeutics Ltd.’s upcoming earnings report date is May 29, 2024 which is in 36 days.
How were Neurosense Therapeutics Ltd.’s earnings last quarter?
Neurosense Therapeutics Ltd. released its earnings results on Apr 05, 2024. The company reported -$0.192 earnings per share for the quarter, beating the consensus estimate of -$0.2 by $0.008.
Is Neurosense Therapeutics Ltd. overvalued?
According to Wall Street analysts Neurosense Therapeutics Ltd.’s price is currently Overvalued.
Does Neurosense Therapeutics Ltd. pay dividends?
Neurosense Therapeutics Ltd. does not currently pay dividends.
What is Neurosense Therapeutics Ltd.’s EPS estimate?
Neurosense Therapeutics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Neurosense Therapeutics Ltd. have?
Neurosense Therapeutics Ltd. has 13,666,042 shares outstanding.
What happened to Neurosense Therapeutics Ltd.’s price movement after its last earnings report?
Neurosense Therapeutics Ltd. reported an EPS of -$0.192 in its last earnings report, beating expectations of -$0.2. Following the earnings report the stock price went down -17.476%.
Which hedge fund is a major shareholder of Neurosense Therapeutics Ltd.?
Currently, no hedge funds are holding shares in NRSN
---
Neurosense Therapeutics Ltd. Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▼ 4.3%
Last 30 Days ▼ 4.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
0.00%
12-Months-Change
Fundamentals
Return on Equity
-602.40%
Trailing 12-Months
Asset Growth
-58.81%
Trailing 12-Months
Company Description
Neurosense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its lead product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
---
NRSN Stock 12 Months Forecast
Average Price Target
―Technical Analysis
Best Analysts Covering NRSN
1 Year
1 Year Success Rate
5/13 ratings generated profit
1 Year Average Return
-1.21%
reiterated a buy rating 4 months ago
Copying Naz Rahman's trades and holding each position for 1 Year would result in 38.46% of your transactions generating a profit, with an average return of -1.21% per trade.
---